New Chromogenic Peptide Substrate for Factor Xa

Aurell, L.; Simonsson, Roger; Arielly, S; Karlsson, Göran; Friberger, P.; Claeson, Göran

doi:10.1055/s-0039-1680664

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chromogenic assays. Chromogenic factor X assays oer an accurate and reliable alternative to clotting assays and became available with the development of the factor Xa-sensitive chromogenic substrates ± S 2222 [62] and S 2337 [63]. There are, however, some concerns about factor X chromogenic assays and in particular the nonspeci®c nature of the substrate which may give rise to spuriously high results [64].…”

Section: Functional Assaysmentioning

confidence: 99%

Factor X and its deficiency states

Perry¹

1997

Haemophilia

View full text Add to dashboard Cite

Factor X is one of the vitamin-K-dependent serine proteases. As a result of its position at the convergence of the intrinsic and extrinsic pathways of the clotting cascade, it plays a crucial role in blood coagulation. Factor X interacts with components of both pathways of coagulation, leading to its activation and the formation of the prothrombinase complex. The gene for factor X has been cloned and sequenced and maps to the long arm of chromosome 13, approximately 2.8 kb downstream of the factor VII gene. Each of the exons of factor X encodes a specific functional domain within the protein. In terms of its gene structure and amino acid sequence, factor X shows significant homology with other vitamin-K-dependent clotting factors, suggesting an origin in some common ancestral protein. Factor X deficiency is one of the rarest of the inherited coagulation disorders. Such deficiencies are inherited in an autosomal recessive manner and are characterized by a variable bleeding tendency. In its homozygous form, factor X deficiency has an estimated prevalence of 1:500 000 but in its heterozygous form it has an estimated frequency of ∼1:500 although affected individuals are often clinically asymptomatic. Acquired deficiencies of factor X are uncommon and in isolation are seen most frequently in patients with amyloidosis and in association with upper respiratory tract infections. Treatment of the deficiency state involves factor X replacement with either fresh frozen plasma or prothrombin complex concentrates. However, the latter may be associated with an increased risk of thrombosis.

show abstract

Section: Functional Assaysmentioning

confidence: 99%

Factor X and its deficiency states

Perry¹

1997

Haemophilia

View full text Add to dashboard Cite

show abstract

“…Bergström and Egberg 12 adapted a Factor X specific assay 4 to the LKB 8600 analyzer using substrate S-2222 and RVV-activated plasma. This test was sensitive to oral anticoagulated plasma, and the results correlated with the TT, r = 0.84.…”

Section: Factor Xa Substrate Assaysmentioning

confidence: 99%

“…Results for 30 warfarin-treated patients correlated well with a Factor Xa clotting assay, r = 0.933 with y = 0.84X + 4.49. Casis et al 16 adapted a Factor X assay using RVV activation 4 for use with the auto matic GEMSAEC III and semiautomatic GEMENI centrifugal analyzers. The CVs for determinations at different factor levels were from 2 to 5%.…”

Section: Factor Xa Substrate Assaysmentioning

confidence: 99%

Development and Clinical Use of Automated Synthetic Substrate Methods for the Evaluation of Coagulation and Fibrinolysis

Mitchell¹

1983

Semin Thromb Hemost

View full text Add to dashboard Cite

“…All these various methods have given broadly similar results with no specific assay being clearly superior to others. The chromogenic substrate S2337 is a rapid acting, highly specific and sensitive substrate for factor X, (Aurell et al 1978). Activity is not inhibited by Antithrombin I11 concentrations up to five times the normal value of plasma, or by polybrene added to neutralize heparin, and it does not measure Pivka X.…”

Section: Discussionmentioning

confidence: 99%

“…Factor X amidolytic activity was measured according to the method of Aurell et al (1978) using the chromogenic substrate S 2337 (Kabi Diagnostica). All reactions were performed at 37°C and at pH 8.3, using a chromogenic substrate concentration of 15 mmol/l, and Russell's viper venom concentration of 0.2 u/ml.…”

Section: Factor X Chromogenic Substrate Assaymentioning

confidence: 99%

Maintenance control of oral anticoagulant therapy by an automated chromogenic substrate assay of factor X

Erskine

Walker

Davidson

2008

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

Summary An amidolytic assay of factor X based on the new chromogenic peptide substrate S 2337 (Kabi Diagnostica) was adapted for use with the Kem‐o‐Mat (Coulter Electronics) automated substrate analyser. Factor X was assayed in 25 healthy controls and in 375 patients on Warfarin therapy. The results in the control group correlated well with a one stage coagulation factor X assay. A good correlation was also found when the S 2337 factor X assay was compared with Thrombotest (Nyegaard & Co.) results in the patients. From the regression line of the S 2337 factor X assay on the Thrombotest results, the comparable range for factor X amidolytic activity in well controlled anticoagulated patients was found to be 22.5–37.5% with this method. Concordant classification of patients by both tests according to proposed therapeutic ranges demonstrated fully concordant information in 76% and fully discordant information in none. This study demonstrates that chromogenic substrate assays for anticoagulant control can be readily automated. Amidolytic assays of factor X based on the S 2337 substrate, therefore, warrant further clinical investigation as a potential method for controlling maintenance oral anticoagulant therapy.

show abstract

New Chromogenic Peptide Substrate for Factor Xa

Cited by 4 publications

References 0 publications

Factor X and its deficiency states

Factor X and its deficiency states

Development and Clinical Use of Automated Synthetic Substrate Methods for the Evaluation of Coagulation and Fibrinolysis

Maintenance control of oral anticoagulant therapy by an automated chromogenic substrate assay of factor X

Contact Info

Product

Resources

About